Author Contributions: Dr Paynter had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Paynter, Chasman, Paré, Buring, Cook, Ridker.
Acquisition of data: Paynter, Chasman, Paré, Buring, Cook, Miletich, Ridker.
Analysis and interpretation of data: Paynter, Chasman, Paré, Buring, Cook, Ridker.
Drafting of the manuscript: Paynter, Chasman, Cook, Ridker.
Critical revision of the manuscript for important intellectual content: Paynter, Chasman, Paré, Buring, Cook, Miletich, Ridker.
Statistical analysis: Paynter, Cook.
Obtained funding: Buring, Ridker.
Administrative, technical, or material support: Paré, Buring, Cook, Miletich, Ridker.
Study supervision: Chasman, Buring, Cook, Ridker.
Financial Disclosures: Drs Buring and Ridker reported receiving investigator-initiated funding from the National Heart, Lung, and Blood Institute, National Cancer Institute, the Donald W. Reynolds Foundation, the Leducq Foundation, Roche Diagnostics, and Amgen Inc. Dr Miletich reported both employment by and stock ownership in Amgen Inc. Dr Ridker reported receiving grant support from AstraZeneca, Novartis, Merck, Abbott, and Sanofi-Aventis; consulting fees from AstraZeneca, Novartis, Merck–Schering-Plough, Sanofi-Aventis, Isis, Siemens, and Vascular Biogenics; and being listed as a coinventor on patents held by Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease, including the use of high-sensitivity C-reactive protein in the evaluation of patients' risk of cardiovascular disease. These patents have been licensed to Siemens and AstraZeneca. None of the other authors reported financial disclosures.
Funding/Support: The Women's Genome Health Study is supported by funds from the National Heart, Lung, and Blood Institute (grants HL 043851 and HL 080467), the National Cancer Institute (grant CA 047988), the Donald W. Reynolds Foundation, and the Leducq Foundation. Genotyping was performed by Amgen Inc. Additional support for DNA extraction, reagents, and data analysis was provided by Roche Diagnostics and Amgen Inc.
Role of the Sponsors: Amgen collaboratively performed genotyping. The other funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.